Does the media favor FTRE or CTKB?

In the previous week, Cytek Biosciences had 1 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for Cytek Biosciences and 7 mentions for Fortrea. Cytek Biosciences' average media sentiment score of 0.52 beat Fortrea's score of -0.01 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortrea 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MRVI or CTKB?

In the previous week, Maravai LifeSciences had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 12 mentions for Maravai LifeSciences and 8 mentions for Cytek Biosciences. Maravai LifeSciences' average media sentiment score of 0.83 beat Cytek Biosciences' score of 0.52 indicating that Maravai LifeSciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or BLFS?

In the previous week, Cytek Biosciences had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for Cytek Biosciences and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.33 beat Cytek Biosciences' score of 0.52 indicating that BioLife Solutions is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive BioLife Solutions 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PSNL or CTKB?

In the previous week, Cytek Biosciences had 1 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Cytek Biosciences and 7 mentions for Personalis. Cytek Biosciences' average media sentiment score of 0.52 beat Personalis' score of -0.44 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cytek Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$4.20 0.00 (0.00%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$4.14 -0.06 (-1.31%)

As of 05:12 AM Eastern

Compare

CTKB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

Should you buy Cytek Biosciences stock or one of its competitors? MarketBeat compares Cytek Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytek Biosciences include Alamar Biosciences (ALMR), Fortrea (FTRE), Maravai LifeSciences (MRVI), BioLife Solutions (BLFS), and Personalis (PSNL). These companies are all part of the "life sciences tools & services" industry.

How does Cytek Biosciences compare to Alamar Biosciences?

Cytek Biosciences (NASDAQ:CTKB) and Alamar Biosciences (NASDAQ:ALMR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

69.5% of Cytek Biosciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cytek Biosciences currently has a consensus target price of $5.56, suggesting a potential upside of 32.44%. Alamar Biosciences has a consensus target price of $30.00, suggesting a potential upside of 5.41%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Alamar Biosciences has lower revenue, but higher earnings than Cytek Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A
Alamar Biosciences	$74.21M	26.58	-$29.82M	-$1.74	N/A

In the previous week, Cytek Biosciences had 8 more articles in the media than Alamar Biosciences. MarketBeat recorded 8 mentions for Cytek Biosciences and 0 mentions for Alamar Biosciences. Cytek Biosciences' average media sentiment score of 0.52 beat Alamar Biosciences' score of 0.00 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cytek Biosciences	Positive
Alamar Biosciences	Neutral

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -38.98%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
Alamar Biosciences	N/A	N/A	N/A

Summary

Cytek Biosciences beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Fortrea?

Fortrea (NASDAQ:FTRE) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

69.5% of Cytek Biosciences shares are owned by institutional investors. 0.7% of Fortrea shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cytek Biosciences has lower revenue, but higher earnings than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortrea	$2.72B	0.64	-$986.20M	-$0.91	N/A
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A

Fortrea currently has a consensus price target of $20.75, indicating a potential upside of 12.59%. Cytek Biosciences has a consensus price target of $5.56, indicating a potential upside of 32.44%. Given Cytek Biosciences' higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortrea	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Cytek Biosciences had 1 more articles in the media than Fortrea. MarketBeat recorded 8 mentions for Cytek Biosciences and 7 mentions for Fortrea. Cytek Biosciences' average media sentiment score of 0.52 beat Fortrea's score of -0.01 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortrea	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a net margin of -3.18% compared to Cytek Biosciences' net margin of -38.98%. Fortrea's return on equity of 10.72% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortrea	-3.18%	10.72%	2.17%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Fortrea has a beta of 1.99, indicating that its stock price is 99% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Summary

Cytek Biosciences beats Fortrea on 9 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Maravai LifeSciences currently has a consensus price target of $5.83, suggesting a potential downside of 6.37%. Cytek Biosciences has a consensus price target of $5.56, suggesting a potential upside of 32.44%. Given Cytek Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	2 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.20
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Maravai LifeSciences has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

In the previous week, Maravai LifeSciences had 4 more articles in the media than Cytek Biosciences. MarketBeat recorded 12 mentions for Maravai LifeSciences and 8 mentions for Cytek Biosciences. Maravai LifeSciences' average media sentiment score of 0.83 beat Cytek Biosciences' score of 0.52 indicating that Maravai LifeSciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	4 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Maravai LifeSciences has a net margin of -37.07% compared to Cytek Biosciences' net margin of -38.98%. Cytek Biosciences' return on equity of -12.40% beat Maravai LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.34%	-7.72%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cytek Biosciences has higher revenue and earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	8.66	-$130.77M	-$0.52	N/A
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A

Summary

Cytek Biosciences beats Maravai LifeSciences on 9 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to BioLife Solutions?

Cytek Biosciences (NASDAQ:CTKB) and BioLife Solutions (NASDAQ:BLFS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

BioLife Solutions has lower revenue, but higher earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A
BioLife Solutions	$106.69M	15.87	-$4.59M	$1.16	29.88

Cytek Biosciences presently has a consensus target price of $5.56, suggesting a potential upside of 32.44%. BioLife Solutions has a consensus target price of $31.38, suggesting a potential downside of 9.48%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cytek Biosciences is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioLife Solutions	1 Sell rating(s)	7 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.20

Cytek Biosciences has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, BioLife Solutions has a beta of 1.93, suggesting that its stock price is 93% more volatile than the broader market.

In the previous week, Cytek Biosciences had 3 more articles in the media than BioLife Solutions. MarketBeat recorded 8 mentions for Cytek Biosciences and 5 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 1.33 beat Cytek Biosciences' score of 0.52 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
BioLife Solutions	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioLife Solutions has a net margin of 53.29% compared to Cytek Biosciences' net margin of -38.98%. BioLife Solutions' return on equity of 2.70% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-38.98%	-12.40%	-9.17%
BioLife Solutions	53.29%	2.70%	2.49%

Summary

BioLife Solutions beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Personalis?

Personalis (NASDAQ:PSNL) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

In the previous week, Cytek Biosciences had 1 more articles in the media than Personalis. MarketBeat recorded 8 mentions for Cytek Biosciences and 7 mentions for Personalis. Cytek Biosciences' average media sentiment score of 0.52 beat Personalis' score of -0.44 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cytek Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

61.9% of Personalis shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cytek Biosciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	21.29	-$81.27M	-$1.09	N/A
Cytek Biosciences	$201.49M	2.71	-$66.54M	-$0.62	N/A

Cytek Biosciences has a net margin of -38.98% compared to Personalis' net margin of -153.84%. Cytek Biosciences' return on equity of -12.40% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
Cytek Biosciences	-38.98%	-12.40%	-9.17%

Personalis has a beta of 2.27, indicating that its stock price is 127% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Personalis presently has a consensus target price of $14.25, indicating a potential upside of 0.64%. Cytek Biosciences has a consensus target price of $5.56, indicating a potential upside of 32.44%. Given Cytek Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Cytek Biosciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Cytek Biosciences beats Personalis on 13 of the 16 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$545.92M	$9.43B	$7.00B	$12.99B
Dividend Yield	N/A	1.45%	2.58%	10.20%
P/E Ratio	-6.77	63.08	270.58	25.05
Price / Sales	2.71	106.76	598.42	84.08
Price / Cash	N/A	26.16	28.89	37.44
Price / Book	1.57	5.09	11.18	6.43
Net Income	-$66.54M	$56.66B	$3.45B	$348.10M
7 Day Performance	-2.55%	3.48%	3.37%	2.66%
1 Month Performance	-9.09%	0.13%	-0.73%	-0.85%
1 Year Performance	4.22%	22.30%	77.30%	23.96%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	2.5209 of 5 stars	$4.20 flat	$5.56 +32.4%	+4.2%	$545.92M	$201.49M	N/A	500	Earnings Report Analyst Forecast
ALMR Alamar Biosciences	1.7699 of 5 stars	$27.11 +0.1%	$30.00 +10.7%	N/A	$1.88B	$87.16M	N/A	222
FTRE Fortrea	2.694 of 5 stars	$17.99 -5.0%	$20.75 +15.3%	+180.1%	$1.80B	$2.72B	N/A	14,300	Gap Down
MRVI Maravai LifeSciences	1.7639 of 5 stars	$6.43 +0.2%	$5.50 -14.5%	+183.2%	$1.66B	$185.74M	N/A	610	Trending News Earnings Report Analyst Forecast
BLFS BioLife Solutions	3.5083 of 5 stars	$32.52 +1.2%	$31.38 -3.5%	+52.8%	$1.57B	$96.21M	N/A	440	Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Fortrea?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Summary

How does Cytek Biosciences compare to Personalis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. ALMR, FTRE, MRVI, BLFS, and PSNL

How does Cytek Biosciences compare to Alamar Biosciences?

Do insiders and institutionals have more ownership in CTKB or ALMR?

Do analysts rate CTKB or ALMR?

Which has higher earnings and valuation, CTKB or ALMR?

Does the media prefer CTKB or ALMR?

Is CTKB or ALMR more profitable?

Summary

How does Cytek Biosciences compare to Fortrea?

Do insiders & institutionals believe in FTRE or CTKB?

Which has higher valuation & earnings, FTRE or CTKB?

Do analysts recommend FTRE or CTKB?

Does the media favor FTRE or CTKB?

Is FTRE or CTKB more profitable?

Which has more risk & volatility, FTRE or CTKB?

Summary

How does Cytek Biosciences compare to Maravai LifeSciences?

Do analysts rate MRVI or CTKB?

Which has more risk & volatility, MRVI or CTKB?

Does the media prefer MRVI or CTKB?

Is MRVI or CTKB more profitable?

Do insiders and institutionals hold more shares of MRVI or CTKB?

Which has preferable valuation and earnings, MRVI or CTKB?

Summary

How does Cytek Biosciences compare to BioLife Solutions?

Do institutionals and insiders have more ownership in CTKB or BLFS?

Which has higher valuation & earnings, CTKB or BLFS?

Do analysts prefer CTKB or BLFS?

Which has more risk & volatility, CTKB or BLFS?

Does the media favor CTKB or BLFS?

Is CTKB or BLFS more profitable?

Summary

How does Cytek Biosciences compare to Personalis?

Does the media refer more to PSNL or CTKB?

Do institutionals & insiders believe in PSNL or CTKB?

Which has stronger valuation and earnings, PSNL or CTKB?

Is PSNL or CTKB more profitable?

Which has more risk & volatility, PSNL or CTKB?

Do analysts rate PSNL or CTKB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools